INT320096

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2010
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 3.85
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (SAE1) nucleus (SAE1) ligase activity (SAE1)
SAE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 10 99.52 Very High Very High Very High
tolerance 20 98.56 Very High Very High Very High
alcohol 30 92.48 High High
aspirin 20 87.08 High High
headache 30 86.32 High High
abdominal pain 10 75.04 Quite High
Arthritis 40 5.00 Very Low Very Low Very Low
Inflammation 21 5.00 Very Low Very Low Very Low
Pain 21 5.00 Very Low Very Low Very Low
Potency 20 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Crystal Associated Disease 760 99.28 Very High Very High Very High
Disease 101 98.92 Very High Very High Very High
Hyperuricemia 330 98.80 Very High Very High Very High
Alcohol Addiction 10 92.72 High High
Liver Disease 10 89.88 High High
Obesity 20 88.76 High High
Hyperlipidemia 10 88.36 High High
Headache 30 86.32 High High
Hypersensitivity 80 84.72 Quite High
Diarrhoea 50 84.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two interim analyses have been published in abstract form, and report that continuous reduction of SUA to levels of 6.0 mg/dL or less lead to significant clinical benefits, and that a larger proportion of patients receiving allopurinol treatment compared with febuxostat 80 and 120 mg/day failed to achieve this goal.54,55 Finally, abstracts from two Japanese phase III studies reported that febuxostat 20 and 40 mg/day reduced SUA in a dose-dependent manner compared with placebo in 103 patients56 and that febuxostat 40 mg/day was more effective in reducing SUA than allopurinol 100 mg twice a day in 256 patients.57
Negative_regulation (reduction) of SUA
1) Confidence 0.12 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0 Pain Relevance 0.04
A phase II abstract from Japan reported a trial in which 128 patients with gout and/or hyperuricemia were randomized to placebo or one of three febuxostat dosages (10, 20, or 40 mg/day).46 All dosages of febuxostat reduced SUA in patients with gout and/or hyperuricemia, regardless of whether they were underexcretors or overproducers of serum urate.
Spec (whether) Negative_regulation (reduced) of SUA associated with hyperuricemia and crystal associated disease
2) Confidence 0.12 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 1.01 Pain Relevance 0.15
The three ancillary studies based on this study and published only in abstract form described reductions in tophi volume (measured by magnetic resonance imaging) in nine patients with decreased SUA levels while on febuxostat,41 good tolerance of febuxostat in allopurinol-intolerant patients,42 and need for at least 3 months colchicine prophylaxis in patients starting febuxostat.43 Two abstract reports of open-label extensions up to 48 months describe continuous efficacy of febuxostat in achieving and maintaining an SUA of less than 6.0 mg/dL, along with a reduction in gout flares and tophi.
Negative_regulation (decreased) of SUA associated with tolerance, crystal associated disease and imagery
3) Confidence 0.12 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.74 Pain Relevance 0.24
Febuxostat, at doses between 80 and 120 mg/day, favorably compares with standard dose allopurinol in reducing SUA.
Negative_regulation (reducing) of SUA
4) Confidence 0.12 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.61 Pain Relevance 0
For example, when we consider a similar number of LFP channels (i.e., 30 and 60 for H464 and H564, respectively) and SUA (i.e., 27 and 56 for H464 and H564, respectively), then the decoding results were 0.82 and 0.83 with LFP and 0.92 and 0.75 with SUA for H464 and H564, respectively.
Negative_regulation (number) of SUA
5) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3006173 Disease Relevance 0 Pain Relevance 0
Becker et al52 analyzed patients treated with febuxostat in the FACT and APEX studies trying to clarify the relationship between postbaseline SUA, a measure of the amount of SUA reduction after initiation of therapy, and the risk of gout flare.
Negative_regulation (reduction) of SUA associated with crystal associated disease
6) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.27 Pain Relevance 0
Two interim analyses have been published in abstract form, and report that continuous reduction of SUA to levels of 6.0 mg/dL or less lead to significant clinical benefits, and that a larger proportion of patients receiving allopurinol treatment compared with febuxostat 80 and 120 mg/day failed to achieve this goal.54,55 Finally, abstracts from two Japanese phase III studies reported that febuxostat 20 and 40 mg/day reduced SUA in a dose-dependent manner compared with placebo in 103 patients56 and that febuxostat 40 mg/day was more effective in reducing SUA than allopurinol 100 mg twice a day in 256 patients.57
Negative_regulation (reducing) of SUA
7) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.07 Pain Relevance 0.03
Secondary endpoints included achievement of an SUA of 6.0 mg/dL or less at each visit and the percentage reduction in SUA concentration at each visit.
Negative_regulation (reduction) of SUA
8) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.56 Pain Relevance 0.09
Becker et al52 analyzed patients treated with febuxostat in the FACT and APEX studies trying to clarify the relationship between postbaseline SUA, a measure of the amount of SUA reduction after initiation of therapy, and the risk of gout flare.
Negative_regulation (reduction) of SUA associated with crystal associated disease
9) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.27 Pain Relevance 0
Two interim analyses have been published in abstract form, and report that continuous reduction of SUA to levels of 6.0 mg/dL or less lead to significant clinical benefits, and that a larger proportion of patients receiving allopurinol treatment compared with febuxostat 80 and 120 mg/day failed to achieve this goal.54,55 Finally, abstracts from two Japanese phase III studies reported that febuxostat 20 and 40 mg/day reduced SUA in a dose-dependent manner compared with placebo in 103 patients56 and that febuxostat 40 mg/day was more effective in reducing SUA than allopurinol 100 mg twice a day in 256 patients.57
Negative_regulation (reduced) of SUA
10) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.06 Pain Relevance 0.03
A selection bias towards patients with a previous poor response to allopurinol is a possibility and finally, due to fact that the primary endpoints of this trial were biochemical (reductions in SUA) instead of clinical (ie, disease-rather than patient-oriented outcomes), the study is difficult to apply to clinical practice where reductions in gout flares are of paramount interest for patients.
Negative_regulation (reductions) of SUA associated with crystal associated disease and disease
11) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899777 Disease Relevance 0.25 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox